Skip to main content
Top
Published in: HAND 3/2010

01-09-2010 | Review Articles of topics

Role of the HLA System in the Pathogenesis of Dupuytren’s Disease

Authors: Sara McCarty, Farhatullah Syed, Ardeshir Bayat

Published in: HAND | Issue 3/2010

Login to get access

Abstract

Dupuytren’s disease (DD) is a familial, fibroproliferative, irreversible, and progressive disease of the palmar fascia, yet with unknown etiology. However, there is compelling evidence which has consistently suggested a genetic ethiopathogenesis given the high occurrence among the Northern European extraction, familial nature, and demonstration of concordance in twins. DD is an incurable, recurrent, and potentially debilitating disease with limited and ineffective treatments. Although a number of possible candidate genes have been investigated including matrix metalloproteinases (MMPs) and transforming growth factor-beta (TGF-β) genes, as yet, no consistent genetic biomarker has been identified for DD. The highly polymorphic human leukocyte antigen (HLA) region is an ideal biomarker target. There have been some coherent data within the literature to suggest a genotype to phenotype association between certain HLA loci and a number of fibrotic disorders such as keloid and scleroderma, markedly with class II molecules and disease pervasiveness and clinical progression. The aim of this review, therefore, was to investigate the evidence indicative of both positive and negative associations between particular HLA alleles and DD. There is a clear association with specific HLA alleles and predilection or protection to DD, though there is a pressing need for further supportive data. The most promising of links to the HLA region in terms of a definitive genetic biomarker is with the class II HLA-DR loci. This paper presents a detailed account of the immunogenetic component of DD and explores the possible mechanisms of association between specific HLA molecules and susceptibility to DD.
Literature
1.
go back to reference Aladin A, Oni JA. Bilateral Dupuytren's contracture in a black patient. Int J Clin Pract. 2001;55(9):641.PubMed Aladin A, Oni JA. Bilateral Dupuytren's contracture in a black patient. Int J Clin Pract. 2001;55(9):641.PubMed
2.
go back to reference Anderson GA. The surgical management of deformities of the hand in leprosy. J Bone Jt Surg, Br Vol. 2006;88(3):290–4.CrossRef Anderson GA. The surgical management of deformities of the hand in leprosy. J Bone Jt Surg, Br Vol. 2006;88(3):290–4.CrossRef
3.
go back to reference Arafa M, Steingold RF, Noble J. The incidence of Dupuytren's disease in patients with rheumatoid arthritis. J Hand Surg, Br and Eur Vol. 1984;9(2):165.CrossRef Arafa M, Steingold RF, Noble J. The incidence of Dupuytren's disease in patients with rheumatoid arthritis. J Hand Surg, Br and Eur Vol. 1984;9(2):165.CrossRef
4.
go back to reference Arinbjarnarson S, Jonsson T, Steinsson K, et al. IgA rheumatoid factor correlates with changes in B and T lymphocyte subsets and disease manifestations in rheumatoid arthritis. J Rheumatol. 1997;24(2):269–74.PubMed Arinbjarnarson S, Jonsson T, Steinsson K, et al. IgA rheumatoid factor correlates with changes in B and T lymphocyte subsets and disease manifestations in rheumatoid arthritis. J Rheumatol. 1997;24(2):269–74.PubMed
5.
go back to reference Arkkila PE, Kantola IM, Viikari JS. Dupuytren's disease: association with chronic diabetic complications. J Rheumatol. 1997;24(1):153.PubMed Arkkila PE, Kantola IM, Viikari JS. Dupuytren's disease: association with chronic diabetic complications. J Rheumatol. 1997;24(1):153.PubMed
6.
go back to reference Baird KS, Alwan WH, Crossan JF, Wojciak B. T-cell-mediated response in Dupuytren's disease. Lancet (British ed). 1993;341(8861):1622–3. Baird KS, Alwan WH, Crossan JF, Wojciak B. T-cell-mediated response in Dupuytren's disease. Lancet (British ed). 1993;341(8861):1622–3.
7.
go back to reference Baird KS, Crossan JF, Ralston SH. Abnormal growth factor and cytokine expression in Dupuytren's contracture. BMJ. 1993;46(5):425–8. Baird KS, Crossan JF, Ralston SH. Abnormal growth factor and cytokine expression in Dupuytren's contracture. BMJ. 1993;46(5):425–8.
8.
go back to reference Bayat A, Alansar A, Hajeer AH, et al. Genetic Susceptibility in Dupuytren's disease: lack of association of a novel transforming growth factor beta 2 polymorphism in Dupuytren's disease. J Hand Surg, Eur Vol. 2002;27(1):47.CrossRef Bayat A, Alansar A, Hajeer AH, et al. Genetic Susceptibility in Dupuytren's disease: lack of association of a novel transforming growth factor beta 2 polymorphism in Dupuytren's disease. J Hand Surg, Eur Vol. 2002;27(1):47.CrossRef
9.
go back to reference Bayat A, Watson JS, Stanley JK. Genetic susceptibility in Dupuytren’s disease: TGF-1 polymorphisms and Dupuytren’s disease. J Bone Joint Surg Br. 2002;84:211–5.CrossRefPubMed Bayat A, Watson JS, Stanley JK. Genetic susceptibility in Dupuytren’s disease: TGF-1 polymorphisms and Dupuytren’s disease. J Bone Joint Surg Br. 2002;84:211–5.CrossRefPubMed
10.
go back to reference Bayat A, Watson JS, Stanley JK, et al. Genetic susceptibility to Dupuytren disease: association of Zf9 transcription factor gene. Plast Reconstr Surg. 2003;111(7):2133.CrossRefPubMed Bayat A, Watson JS, Stanley JK, et al. Genetic susceptibility to Dupuytren disease: association of Zf9 transcription factor gene. Plast Reconstr Surg. 2003;111(7):2133.CrossRefPubMed
11.
go back to reference Bayat A, Stanley JK, Watson JS, Ferguson MWJ, Ollier WER. Genetic susceptibility to Dupuytren's disease: transforming growth factor beta receptor (TGF R) gene polymorphisms and Dupuytren's disease. Br J Plast Surg. 2003;56(4):328–33.CrossRefPubMed Bayat A, Stanley JK, Watson JS, Ferguson MWJ, Ollier WER. Genetic susceptibility to Dupuytren's disease: transforming growth factor beta receptor (TGF R) gene polymorphisms and Dupuytren's disease. Br J Plast Surg. 2003;56(4):328–33.CrossRefPubMed
12.
go back to reference Bayat A, Walter J, Lambe H, et al. Identification of a novel mitochondrial mutation in Dupuytren's disease using multiplex DHPLC. Plast Reconstr Surg. 2005;115(1):134.PubMed Bayat A, Walter J, Lambe H, et al. Identification of a novel mitochondrial mutation in Dupuytren's disease using multiplex DHPLC. Plast Reconstr Surg. 2005;115(1):134.PubMed
13.
go back to reference Bazin S, Lous MLE, Duance VC, et al. Biochemistry and histology of the connective tissue of Dupuytren's disease lesions. Eur J Clin Investig. 1980;10(S1):9–16.CrossRef Bazin S, Lous MLE, Duance VC, et al. Biochemistry and histology of the connective tissue of Dupuytren's disease lesions. Eur J Clin Investig. 1980;10(S1):9–16.CrossRef
14.
go back to reference Bodmer WF, Browning MJ, Krausa P, et al. Tumor escape from immune response by variation in HLA expression and other mechanisms. Ann NY Acad Sci. 1993;690:42–9 (1 Specific Immunotherapy of Cancer with Vaccines).CrossRefPubMed Bodmer WF, Browning MJ, Krausa P, et al. Tumor escape from immune response by variation in HLA expression and other mechanisms. Ann NY Acad Sci. 1993;690:42–9 (1 Specific Immunotherapy of Cancer with Vaccines).CrossRefPubMed
15.
go back to reference Brown JJ, Ollier W, Thomson W, Bayat A. Positive association of HLA-DRB1* 15 with Dupuytren's disease in Caucasians. Tissue Antigens. 2008;72(2):166.CrossRefPubMed Brown JJ, Ollier W, Thomson W, Bayat A. Positive association of HLA-DRB1* 15 with Dupuytren's disease in Caucasians. Tissue Antigens. 2008;72(2):166.CrossRefPubMed
16.
go back to reference Browning MJ, Krausa P, Rowan A, et al. Loss of human leukocyte antigen expression on colorectal tumor cell lines: implications for anti-tumor immunity and immunotherapy. J Immunother Emphasis Tumor Immunol. 1993;14(3):163.PubMed Browning MJ, Krausa P, Rowan A, et al. Loss of human leukocyte antigen expression on colorectal tumor cell lines: implications for anti-tumor immunity and immunotherapy. J Immunother Emphasis Tumor Immunol. 1993;14(3):163.PubMed
17.
go back to reference Bulstrode NW, Bisson M, Jemec B, et al. A Prospective randomised clinical trial of the intra-operative use of 5-fluorouracil on the outcome of Dupuytren's disease. J Hand Surg. 2004;29(1):18–21. Bulstrode NW, Bisson M, Jemec B, et al. A Prospective randomised clinical trial of the intra-operative use of 5-fluorouracil on the outcome of Dupuytren's disease. J Hand Surg. 2004;29(1):18–21.
18.
go back to reference Burge P. Genetics of Dupuytren's disease. Hand Clin. 1999;15(1):63–71.PubMed Burge P. Genetics of Dupuytren's disease. Hand Clin. 1999;15(1):63–71.PubMed
20.
go back to reference Chouvardas VG, Miliou AN, and Hatalis MK. Tactile displays: a short overview and recent developments. In Proceedings of the ICTA. 2005. p. 246-251. Chouvardas VG, Miliou AN, and Hatalis MK. Tactile displays: a short overview and recent developments. In Proceedings of the ICTA. 2005. p. 246-251.
21.
go back to reference Concha A, Esteban F, Cabrera T, Ruiz-Cabello F, Garrido F. Tumor aggressiveness and MHC class I and II antigens in laryngeal and breast cancer. Semin Cancer Biol. 1991;2:47–54.PubMed Concha A, Esteban F, Cabrera T, Ruiz-Cabello F, Garrido F. Tumor aggressiveness and MHC class I and II antigens in laryngeal and breast cancer. Semin Cancer Biol. 1991;2:47–54.PubMed
22.
go back to reference Connelly TJ. Development of Peyronie's and Dupuytren's diseases in an individual after single episodes of trauma: a case report and review of the literature. J Am Acad Dermatol. 1999;41(1):106.CrossRefPubMed Connelly TJ. Development of Peyronie's and Dupuytren's diseases in an individual after single episodes of trauma: a case report and review of the literature. J Am Acad Dermatol. 1999;41(1):106.CrossRefPubMed
23.
go back to reference Cordova A, Tripoli M, Corradino B, Napoli P, Moschella F. Dupuytren's contracture: an update of biomolecular aspects and therapeutic perspectives. J Hand Surg. 2005;30(6):557–62. Cordova A, Tripoli M, Corradino B, Napoli P, Moschella F. Dupuytren's contracture: an update of biomolecular aspects and therapeutic perspectives. J Hand Surg. 2005;30(6):557–62.
24.
go back to reference Cromme FV, van Bommel PF, Walboomers JM, et al. Differences in MHC and TAP-1 expression in cervical cancer lymph node metastases as compared with the primary tumours. Br J Cancer. 1994;69(6):1176.PubMed Cromme FV, van Bommel PF, Walboomers JM, et al. Differences in MHC and TAP-1 expression in cervical cancer lymph node metastases as compared with the primary tumours. Br J Cancer. 1994;69(6):1176.PubMed
25.
go back to reference Devine CJJ, Somers KD, Jordan GH, Schlossberg SM. Proposal: trauma as the cause of the Peyronie's lesion. J Urol. 1997;157(1):285–90.CrossRefPubMed Devine CJJ, Somers KD, Jordan GH, Schlossberg SM. Proposal: trauma as the cause of the Peyronie's lesion. J Urol. 1997;157(1):285–90.CrossRefPubMed
26.
go back to reference Early PF. Population studies in Dupuytren's contracture. J Bone Jt Surg, Br Vol. 1962;44(3):602–13. Early PF. Population studies in Dupuytren's contracture. J Bone Jt Surg, Br Vol. 1962;44(3):602–13.
27.
go back to reference Gabbiani G, Majno G. Dupuytren's contracture: fibroblast contraction?: An ultrastructural study. Am J Pathol. 1972;66(1):131.PubMed Gabbiani G, Majno G. Dupuytren's contracture: fibroblast contraction?: An ultrastructural study. Am J Pathol. 1972;66(1):131.PubMed
28.
go back to reference Goldsby RA, Kindt TJ, Osborne BA. Major histocompatibility complex. Kuby Immunology, fourth edition. New York, Freeman, 2000;p186. Goldsby RA, Kindt TJ, Osborne BA. Major histocompatibility complex. Kuby Immunology, fourth edition. New York, Freeman, 2000;p186.
29.
go back to reference Gudmundsson KG, Arngrimsson R, Arinbjarnarson S, Olafsson A, Jonsson T. T-and B-lymphocyte subsets in patients with Dupuytren's disease Correlations with disease severity. J Hand Surg. 1998;23(6):724–7. Gudmundsson KG, Arngrimsson R, Arinbjarnarson S, Olafsson A, Jonsson T. T-and B-lymphocyte subsets in patients with Dupuytren's disease Correlations with disease severity. J Hand Surg. 1998;23(6):724–7.
30.
go back to reference Hu FZ, Nystrom A, Ahmed A, et al. Mapping of an autosomal dominant gene for Dupuytren's contracture to chromosome 16q in a Swedish family. Clin Genet. 2005;68(5):424.CrossRefPubMed Hu FZ, Nystrom A, Ahmed A, et al. Mapping of an autosomal dominant gene for Dupuytren's contracture to chromosome 16q in a Swedish family. Clin Genet. 2005;68(5):424.CrossRefPubMed
31.
go back to reference Hueston J. The role of the skin in Dupuytren's disease. Ann R Coll Surg Engl. 1985;67(6):372.PubMed Hueston J. The role of the skin in Dupuytren's disease. Ann R Coll Surg Engl. 1985;67(6):372.PubMed
32.
go back to reference Hunter T, Shanahan WR Jr, Robertson GA, Stranc MF, Schroeder ML. The distribution of histocompatibility antigens in patients with Dupuytren's contracture. Arthritis Rheum. 1981;24(9):1218–9.CrossRefPubMed Hunter T, Shanahan WR Jr, Robertson GA, Stranc MF, Schroeder ML. The distribution of histocompatibility antigens in patients with Dupuytren's contracture. Arthritis Rheum. 1981;24(9):1218–9.CrossRefPubMed
33.
go back to reference Joko S, Numaga J, Maeda H. Immunogenetics of uveitis in leprosy. Jpn J Ophthalmol. 1999;43:97–102.CrossRefPubMed Joko S, Numaga J, Maeda H. Immunogenetics of uveitis in leprosy. Jpn J Ophthalmol. 1999;43:97–102.CrossRefPubMed
34.
go back to reference Jozsa L, Demel S, Pinter T, et al. Immunopathological study on palmar aponeurosis in Dupuytren's disease. Acta Histochem. 1988;83(2):153.PubMed Jozsa L, Demel S, Pinter T, et al. Immunopathological study on palmar aponeurosis in Dupuytren's disease. Acta Histochem. 1988;83(2):153.PubMed
35.
go back to reference Kaklamanis L, Leek R, Koukourakis M, Gatter KC, Harris AL. Loss of transporter in antigen processing 1 transport protein and major histocompatibility complex class I molecules in metastatic versus primary breast cancer. Cancer Res. 1995;55(22):5191–4.PubMed Kaklamanis L, Leek R, Koukourakis M, Gatter KC, Harris AL. Loss of transporter in antigen processing 1 transport protein and major histocompatibility complex class I molecules in metastatic versus primary breast cancer. Cancer Res. 1995;55(22):5191–4.PubMed
36.
go back to reference Klimiuk PS, Clague RB, Grennan DM, et al. Autoimmunity to native type II collagen–a distinct genetic subset of rheumatoid arthritis. J Rheumatol. 1985;12(5):865.PubMed Klimiuk PS, Clague RB, Grennan DM, et al. Autoimmunity to native type II collagen–a distinct genetic subset of rheumatoid arthritis. J Rheumatol. 1985;12(5):865.PubMed
37.
go back to reference Kloen P. New insights in the development of Dupuytren’s contracture: A review. Br J Plast Surg. 1999;52(8):629–35.CrossRefPubMed Kloen P. New insights in the development of Dupuytren’s contracture: A review. Br J Plast Surg. 1999;52(8):629–35.CrossRefPubMed
38.
go back to reference Kloen P, Jennings CL, Gebhardt MC, Springfield DS, Mankin HJ. Transforming growth factor-: possible roles in Dupuytren's contracture. J Hand Surg. 1995;20(1):101–8.CrossRef Kloen P, Jennings CL, Gebhardt MC, Springfield DS, Mankin HJ. Transforming growth factor-: possible roles in Dupuytren's contracture. J Hand Surg. 1995;20(1):101–8.CrossRef
39.
go back to reference Krüger-Sayn M, Porzberg G, and Paschmeyer HD. Does the open palm technique for surgery of Dupuytren's contracture extend treatment and disability duration? A retrospective study. Handchirurgie, Mikrochirurgie, plastische Chirurgie: Organ der Deutschsprachigen Arbeitsgemeinschaft für Handchirurgie: Organ der Deutschsprachigen Arbeitsgemeinschaft für Mikrochirurgie der Peripheren Nerven und Gefässe: Organ der Vereinigung der Deutschen Plastischen Chirurgen. 1998;30(4):269. Krüger-Sayn M, Porzberg G, and Paschmeyer HD. Does the open palm technique for surgery of Dupuytren's contracture extend treatment and disability duration? A retrospective study. Handchirurgie, Mikrochirurgie, plastische Chirurgie: Organ der Deutschsprachigen Arbeitsgemeinschaft für Handchirurgie: Organ der Deutschsprachigen Arbeitsgemeinschaft für Mikrochirurgie der Peripheren Nerven und Gefässe: Organ der Vereinigung der Deutschen Plastischen Chirurgen. 1998;30(4):269.
40.
go back to reference Ling RSM. The genetic factor in Dupuytren's disease. J Bone Jt Surg, Br Vol. 1963;45(4):709–18. Ling RSM. The genetic factor in Dupuytren's disease. J Bone Jt Surg, Br Vol. 1963;45(4):709–18.
41.
go back to reference Liss GM, Stock SR. Can Dupuytren's contracture be work-related?: review of the evidence. Am J Ind Med. 1996;29(5):521–32.CrossRefPubMed Liss GM, Stock SR. Can Dupuytren's contracture be work-related?: review of the evidence. Am J Ind Med. 1996;29(5):521–32.CrossRefPubMed
42.
go back to reference Mann DL, Murray C, O'Donnell M, Blattner WA, Goedert JJ. HLA antigen frequencies in HIV-1-related Kaposi's sarcoma. J Acquir Immune Defic Syndr. 1990;3:S51.PubMed Mann DL, Murray C, O'Donnell M, Blattner WA, Goedert JJ. HLA antigen frequencies in HIV-1-related Kaposi's sarcoma. J Acquir Immune Defic Syndr. 1990;3:S51.PubMed
43.
go back to reference Manson JS. Heredity and dupuytren's contraction. Br Med J. 1931;2(3678):11.CrossRef Manson JS. Heredity and dupuytren's contraction. Br Med J. 1931;2(3678):11.CrossRef
44.
go back to reference Matés JM, Sánchez-Jiménez FM. Role of reactive oxygen species in apoptosis: implications for cancer therapy. Int J Biochem Cell Biol. 2000;32(2):157–70.CrossRefPubMed Matés JM, Sánchez-Jiménez FM. Role of reactive oxygen species in apoptosis: implications for cancer therapy. Int J Biochem Cell Biol. 2000;32(2):157–70.CrossRefPubMed
45.
go back to reference McFarlane RM. On the origin and spread of Dupuytren's disease. J Hand Surg. 2002;27(3):385–90.CrossRef McFarlane RM. On the origin and spread of Dupuytren's disease. J Hand Surg. 2002;27(3):385–90.CrossRef
46.
go back to reference Meek RMD, McLellan S, Crossan JF. Dupuytren's disease A model for the mechanism of fibrosis and its modulation by steroids. J Bone Jnt Surg Br Vol. 1999;81(4):732–8.CrossRef Meek RMD, McLellan S, Crossan JF. Dupuytren's disease A model for the mechanism of fibrosis and its modulation by steroids. J Bone Jnt Surg Br Vol. 1999;81(4):732–8.CrossRef
47.
go back to reference Meek RMD, McLellan S, Reilly J, Crossan JF. The effect of steroids on Dupuytren’s disease: role of programmed cell death. J Hand Surg, Br and Eur Vol. 2002;27(3):270–3.CrossRef Meek RMD, McLellan S, Reilly J, Crossan JF. The effect of steroids on Dupuytren’s disease: role of programmed cell death. J Hand Surg, Br and Eur Vol. 2002;27(3):270–3.CrossRef
48.
go back to reference Mikkelsen OA. Dupuytren’s disease the influence of occupation and previous hand injuries. JHand Surg, Eur Vol. 1978;10(1):1–8. Mikkelsen OA. Dupuytren’s disease the influence of occupation and previous hand injuries. JHand Surg, Eur Vol. 1978;10(1):1–8.
49.
50.
go back to reference Murrell GAC, Hueston JT. Aetiology of Dupuytren's contracture. ANZ J Surg. 1990;60(4):247–52.CrossRef Murrell GAC, Hueston JT. Aetiology of Dupuytren's contracture. ANZ J Surg. 1990;60(4):247–52.CrossRef
51.
go back to reference Nau R, Brück W. Neuronal injury in bacterial meningitis: mechanisms and implications for therapy. Trends Neurosci. 2002;25(1):38–45.CrossRefPubMed Nau R, Brück W. Neuronal injury in bacterial meningitis: mechanisms and implications for therapy. Trends Neurosci. 2002;25(1):38–45.CrossRefPubMed
52.
go back to reference Neumüller J, Menzel J, Millesi H. Prevalence of HLA-DR3 and autoantibodies to connective tissue components in Dupuytren's contracture. Clin Immunol Immunopathol. 1994;71(2):142–8.CrossRefPubMed Neumüller J, Menzel J, Millesi H. Prevalence of HLA-DR3 and autoantibodies to connective tissue components in Dupuytren's contracture. Clin Immunol Immunopathol. 1994;71(2):142–8.CrossRefPubMed
53.
go back to reference Noble J, Arafa M, Royle SG, McGeorge G, Crank S. The association between alcohol, hepatic pathology and Dupuytren's disease. J Hand Surg. 1992;17(1):71.CrossRef Noble J, Arafa M, Royle SG, McGeorge G, Crank S. The association between alcohol, hepatic pathology and Dupuytren's disease. J Hand Surg. 1992;17(1):71.CrossRef
54.
go back to reference Pentland AP, Anderson TF. Plantar fibromatosis responds to intralesional steroids. J Am Acad Dermatol. 1985;12(1):212–4.CrossRefPubMed Pentland AP, Anderson TF. Plantar fibromatosis responds to intralesional steroids. J Am Acad Dermatol. 1985;12(1):212–4.CrossRefPubMed
55.
go back to reference Pereira RS, Black CM, Turner SM, Spencer JD. Antibodies to collagen types I-VI in Dupuytren's contracture. J Hand Surg, Eur Vol. 1986;11(1):58.CrossRef Pereira RS, Black CM, Turner SM, Spencer JD. Antibodies to collagen types I-VI in Dupuytren's contracture. J Hand Surg, Eur Vol. 1986;11(1):58.CrossRef
56.
go back to reference Phelps RG, Jones V, Turner AN, Rees AJ. Properties of HLA class II molecules divergently associated with Goodpasture's disease. Int Immunol. 2000;12(8):1135–43.CrossRefPubMed Phelps RG, Jones V, Turner AN, Rees AJ. Properties of HLA class II molecules divergently associated with Goodpasture's disease. Int Immunol. 2000;12(8):1135–43.CrossRefPubMed
57.
go back to reference Riolo J, Young VL, Ueda K, Pidgeon L. Dupuytren's Contracture. South Med J. 1991;84(8):983.PubMed Riolo J, Young VL, Ueda K, Pidgeon L. Dupuytren's Contracture. South Med J. 1991;84(8):983.PubMed
58.
go back to reference Sawyer RG, Spengler MD, Adams RB, Pruett TL. The peritoneal environment during infection. Ann Surg. 1991;2(1):3. Sawyer RG, Spengler MD, Adams RB, Pruett TL. The peritoneal environment during infection. Ann Surg. 1991;2(1):3.
59.
go back to reference Schendel DJ, Gansbacher B, Oberneder R, et al. Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes. I. HLA-A2-restricted recognition of autologous and allogeneic tumor lines. J Immunol. 1993;151(8):4209–20.PubMed Schendel DJ, Gansbacher B, Oberneder R, et al. Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes. I. HLA-A2-restricted recognition of autologous and allogeneic tumor lines. J Immunol. 1993;151(8):4209–20.PubMed
60.
go back to reference Shah M, Foreman DM, Ferguson MWJ. Control of scarring in adult wounds by neutralising antibody to transforming growth factor [beta]. Lancet. 1992;339(8787):213–4.CrossRefPubMed Shah M, Foreman DM, Ferguson MWJ. Control of scarring in adult wounds by neutralising antibody to transforming growth factor [beta]. Lancet. 1992;339(8787):213–4.CrossRefPubMed
61.
go back to reference Shelley ED. Response of Dupuytren's contracture to high-potency topical steroid. Lancet (British ed). 1993;342(8867):366–6. Shelley ED. Response of Dupuytren's contracture to high-potency topical steroid. Lancet (British ed). 1993;342(8867):366–6.
62.
go back to reference Spencer JD, Walsh KI. Histocompatibility antigen patterns in Dupuytren's contracture. J Hand Surg, Eur Vol. 1984;9(3):276.CrossRef Spencer JD, Walsh KI. Histocompatibility antigen patterns in Dupuytren's contracture. J Hand Surg, Eur Vol. 1984;9(3):276.CrossRef
63.
go back to reference Spring M, Fleck H, Cohen BD. Dupuytren's contracture. Warning of diabetes? NY State J Med. 1970;70(9):1037. Spring M, Fleck H, Cohen BD. Dupuytren's contracture. Warning of diabetes? NY State J Med. 1970;70(9):1037.
64.
go back to reference Tait BD, Mackay IR. HLA phenotypes in Dupuytren's contracture. Tissue Antigens. 1982;19(3):240–1.CrossRefPubMed Tait BD, Mackay IR. HLA phenotypes in Dupuytren's contracture. Tissue Antigens. 1982;19(3):240–1.CrossRefPubMed
65.
66.
go back to reference Tomasek JJ, Vaughan MB, Haaksma CJ. Cellular structure and biology of Dupuytren's disease. Hand Clin. 1999;15(1):21–34.PubMed Tomasek JJ, Vaughan MB, Haaksma CJ. Cellular structure and biology of Dupuytren's disease. Hand Clin. 1999;15(1):21–34.PubMed
67.
go back to reference Williams PL, Dann J, James DCO, Timlin D. Histocompatibility antigens in subgroups of Dupuytren's contracture. Br Soc Rheum. 1983;22:60–1.CrossRef Williams PL, Dann J, James DCO, Timlin D. Histocompatibility antigens in subgroups of Dupuytren's contracture. Br Soc Rheum. 1983;22:60–1.CrossRef
68.
go back to reference Wintzer HO, Benzing M, Von Kleist S. Lacking prognostic significance of beta 2-microglobulin. MHC class I and class II antigen expression in breast carcinomas. Br J Cancer. 1990;62(2):289.PubMed Wintzer HO, Benzing M, Von Kleist S. Lacking prognostic significance of beta 2-microglobulin. MHC class I and class II antigen expression in breast carcinomas. Br J Cancer. 1990;62(2):289.PubMed
Metadata
Title
Role of the HLA System in the Pathogenesis of Dupuytren’s Disease
Authors
Sara McCarty
Farhatullah Syed
Ardeshir Bayat
Publication date
01-09-2010
Publisher
Springer-Verlag
Published in
HAND / Issue 3/2010
Print ISSN: 1558-9447
Electronic ISSN: 1558-9455
DOI
https://doi.org/10.1007/s11552-009-9255-y

Other articles of this Issue 3/2010

HAND 3/2010 Go to the issue